Document is current
Any future updates will be listed below
-
Authors
Dufraing, Kelly http://orcid.org/0000-0002-0418-587X
Van Casteren, Kaat http://orcid.org/0000-0002-6339-9771
Breyne, Joke
D’Haene, Nicky
Van Campenhout, Claude
Vander Borght, Sara
Zwaenepoel, Karen
Rouleau, Etienne
Schuuring, Ed http://orcid.org/0000-0003-3655-143X
von der Thüsen, Jan
Dequeker, Elisabeth
- License Information
-
More Information
Article History
Received: 16 January 2021
Accepted: 21 May 2021
First Online: 6 July 2022
Declarations
:
: Not applicable since it concerned a retrospective observational study on anonymized data. The requirement for ethical approval for the present study was waived by The Research Ethics Committee of KU/UZ Leuven and an official waiver was obtained since the study is of retrospective and observational nature with patient data. No informed consent was necessary for this study since no patients or identifying personal data will be used or accessed. For the analysis of the request forms and reports, written permission was obtained from the visited hospitals to access anonymized data. The data (request forms and result reports) were anonymized and printed from the laboratory information system by a representative from the visited laboratory. Access to the original dataset in the laboratory information system was not permitted to assure the privacy of the patients. For a second study part, we developed a survey for collecting general information (opinions and questions regarding their requesting and reporting procedures) from the clinicians and molecular pathologists. Informed consent was obtained from all the participants for the study. Only aggregate data were collected, which were anonymized prior to use. All participants consented to the use of these aggregate data.
: Not applicable.
: ES received honoraria for consultancy/advisory board from AstraZeneca, Roche, Pfizer, Bayer, Novartis, BMS, MSD/Merck, BioRad, Illumina, Ageno BioSciences, Janssen Cilag (Johnson&Johnson), BioCartis; speaker’s fee AstraZeneca, Roche, Pfizer, Novartis, BioRad, Illumina, Ageno BioSciences, BioCartis; (unrestricted) grants from Boehringer Ingelheim, BMS, Biocartis, BioRad, Ageno BioSciences and Roche (All outside the submitted work and fees to UMCG). JvdT is a member of the advisory boards of BMS, MSD and Roche. EDQ received a research grant from AstraZeneca. KD, KvC, JB, NDH, CVC, SVB, ER and KZ have nothing to declare.
